Rapport Therapeutics to Present Seizure Treatment Data

Rapport Therapeutics will present new Phase 2 follow-up data for its focal onset seizure treatment, RAP-219, at the 2026 American Academy of Neurology Annual Meeting. The presentation will offer insights into the long-term efficacy and safety profile of RAP-219 in patients with focal onset seizures. This data is crucial for advancing the clinical development of the drug and informing potential regulatory submissions. Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders, aiming to address significant unmet medical needs.